Williams Jones Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Williams Jones Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133K	Hold	101,300	–	–	﹤0.01%	525
2026 Q1	$160K	Hold	101,300	–	–	﹤0.01%	484
2025 Q4	$169K	Hold	101,300	–	–	﹤0.01%	477
2025 Q3	$171K	Hold	101,300	–	–	﹤0.01%	471
2025 Q2	$91.9K	Hold	101,300	–	–	﹤0.01%	489
2025 Q1	$45.7K	Hold	101,300	–	–	﹤0.01%	483
2024 Q4	$50.9K	Hold	101,300	–	–	﹤0.01%	486
2024 Q3	$91.7K	Hold	101,300	–	–	﹤0.01%	518
2024 Q2	$101K	Hold	101,300	–	–	﹤0.01%	500
2024 Q1	$150K	Hold	101,300	–	–	﹤0.01%	512
2023 Q4	$110K	Hold	101,300	–	–	﹤0.01%	514
2023 Q3	$120K	Hold	101,300	–	–	﹤0.01%	510
2023 Q2	$143K	Hold	101,300	–	–	﹤0.01%	494
2023 Q1	$152K	Hold	101,300	–	–	﹤0.01%	521
2022 Q4	$119K	Hold	101,300	–	–	﹤0.01%	520
2022 Q3	$114K	Hold	101,300	–	–	﹤0.01%	530
2022 Q2	$160K	Hold	101,300	–	–	﹤0.01%	532
2022 Q1	$156K	Hold	101,300	–	–	﹤0.01%	495
2021 Q4	$248K	Buy	+101,300	New	+$237K	﹤0.01%	431
2021 Q2	–	Sell	-101,300	Closed	-$238K	–	510
2021 Q1	$238K	Hold	101,300	–	–	﹤0.01%	430
2020 Q4	$178K	Hold	101,300	–	–	﹤0.01%	441
2020 Q3	$95K	Hold	101,300	–	–	﹤0.01%	417
2020 Q2	$88K	Hold	101,300	–	–	﹤0.01%	397
2020 Q1	$84K	Hold	101,300	–	–	﹤0.01%	361
2019 Q4	$90K	Sell	101,300 -361	-0.4%	-$301	﹤0.01%	431
2019 Q3	$100K	Buy	+101,661	New	+$105K	﹤0.01%	413

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Williams Jones Wealth Management's LCTX Position: Q2 2026 in Review

Williams Jones Wealth Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 101,300 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #525.

Williams Jones Wealth Management first reported a position in LCTX in Q3 2019 and has held it in 26 quarters since. The position peaked at $248K in Q4 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Williams Jones Wealth Management held 101,300 shares of Lineage Cell Therapeutics worth $133K as of Q2 2026.
Williams Jones Wealth Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Williams Jones Wealth Management's portfolio in Q2 2026, its #525 holding.
Williams Jones Wealth Management first reported a position in Lineage Cell Therapeutics in Q3 2019 and has held it in 26 quarters since.
Williams Jones Wealth Management's Lineage Cell Therapeutics position peaked at $248K in Q4 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Williams Jones Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.